Ignite Creation Date:
2025-12-24 @ 2:12 PM
Ignite Modification Date:
2026-01-19 @ 5:52 PM
Study NCT ID:
NCT02115295
Status:
RECRUITING
Last Update Posted:
2025-11-06
First Post:
2014-04-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Acute Biphenotypic Leukemia | View |
| None | Acute Myeloid Leukemia | View |
| None | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Blasts 10 Percent or More of Bone Marrow Nucleated Cells | View |
| None | Blasts 10 Percent or More of Peripheral Blood White Cells | View |
| None | de Novo Myelodysplastic Syndrome | View |
| None | Myelodysplastic Syndrome | View |
| None | Previously Treated Myelodysplastic Syndrome | View |
| None | Recurrent Acute Myeloid Leukemia | View |
| None | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Secondary Acute Myeloid Leukemia | View |
| None | Untreated Adult Acute Myeloid Leukemia | View |
Keywords: